130 related articles for article (PubMed ID: 1968353)
21. Kunxian capsules in the treatment of patients with ankylosing spondylitis: a randomized placebo-controlled clinical trial.
Li Q; Li L; Bi L; Xiao C; Lin Z; Cao S; Liao Z; Gu J
Trials; 2016 Jul; 17(1):337. PubMed ID: 27449221
[TBL] [Abstract][Full Text] [Related]
22. Associations between inflammation, nocturnal back pain and fatigue in ankylosing spondylitis and improvements with etanercept therapy.
Hammoudeh M; Zack DJ; Li W; Stewart VM; Koenig AS
J Int Med Res; 2013 Aug; 41(4):1150-9. PubMed ID: 23803306
[TBL] [Abstract][Full Text] [Related]
23. Prospective trial comparing the use of sulphasalazine and auranofin as second line drugs in patients with rheumatoid arthritis.
Porter D; Madhok R; Hunter JA; Capell HA
Ann Rheum Dis; 1992 Apr; 51(4):461-4. PubMed ID: 1350192
[TBL] [Abstract][Full Text] [Related]
24. Sulfasalazine in the treatment of ankylosing spondylitis. A twenty-six-week, placebo-controlled clinical trial.
Nissilä M; Lehtinen K; Leirisalo-Repo M; Luukkainen R; Mutru O; Yli-Kerttula U
Arthritis Rheum; 1988 Sep; 31(9):1111-6. PubMed ID: 2901839
[TBL] [Abstract][Full Text] [Related]
25. Relative value of erythrocyte sedimentation rate and C-reactive protein in assessment of disease activity in ankylosing spondylitis.
Spoorenberg A; van der Heijde D; de Klerk E; Dougados M; de Vlam K; Mielants H; van der Tempel H; van der Linden S
J Rheumatol; 1999 Apr; 26(4):980-4. PubMed ID: 10229432
[TBL] [Abstract][Full Text] [Related]
26. Circulating inhibitor bound elastase in patients with ankylosing spondylitis and rheumatoid arthritis and the influence of sulphasalazine treatment.
Feltelius N; Hällgren R
Ann Rheum Dis; 1988 Jan; 47(1):10-4. PubMed ID: 2894204
[TBL] [Abstract][Full Text] [Related]
27. Desensitization to sulphasalazine in patients with arthritis.
Koski JM
Clin Exp Rheumatol; 1993; 11(2):169-70. PubMed ID: 8099541
[TBL] [Abstract][Full Text] [Related]
28. Sensitivity and discriminatory ability of the Ankylosing Spondylitis Disease Activity Score in patients treated with etanercept or sulphasalazine in the ASCEND trial.
van der Heijde D; Braun J; Dougados M; Sieper J; Pedersen R; Szumski A; Koenig AS
Rheumatology (Oxford); 2012 Oct; 51(10):1894-905. PubMed ID: 22772319
[TBL] [Abstract][Full Text] [Related]
29. Expression of IL-2 and IL-11 and its significance in patients with ankylosing spondylitis.
Liu F; Wang F; Wang CC; Li N; Li SF
Asian Pac J Trop Med; 2013 Jan; 6(1):76-8. PubMed ID: 23317891
[TBL] [Abstract][Full Text] [Related]
30. Add-On Effects of Conventional Synthetic Disease-Modifying Anti-Rheumatic Drugs in Ankylosing Spondylitis: Data from a Real-World Registered Study in China.
Man S; Ji X; Wang Y; Ma Y; Hu Z; Zhu J; Zhang J; Huang F
Med Sci Monit; 2020 Jan; 26():e921055. PubMed ID: 31959738
[TBL] [Abstract][Full Text] [Related]
31. C-reactive protein, ESR, and klebsiella in ankylosing spondylitis.
Cowling P; Ebringer R; Cawdell D; Ishii M; Ebringer A
Ann Rheum Dis; 1980 Feb; 39(1):45-9. PubMed ID: 7377858
[TBL] [Abstract][Full Text] [Related]
32. Efficacy and safety of mesalazine (Salofalk) in an open study of 20 patients with ankylosing spondylitis.
van Denderen JC; van der Horst-Bruinsma I; Bezemer PD; Dijkmans BA
J Rheumatol; 2003 Jul; 30(7):1558-60. PubMed ID: 12858458
[TBL] [Abstract][Full Text] [Related]
33. [Effects of infliximab and etanercept, two types of anti-tumor necrosis factor-alpha inhibitor on serum level of matrix metalloproteinase 3 expression in patients with ankylosing spondylitis].
Yang CH; Huang F; Deng XH; Zhang JL; Zhang LY; Guo JH; Liang DF; Wang LS; Zhang YM
Zhonghua Yi Xue Za Zhi; 2006 Sep; 86(35):2451-4. PubMed ID: 17156669
[TBL] [Abstract][Full Text] [Related]
34. [The value of erythrocyte sedimentation rate and C-reactive protein in evaluating disease activity in ankylosing spondylitis].
Liu B; Guo CY; Liu WQ; Wu N; Xing Q
Zhonghua Nei Ke Za Zhi; 2005 Aug; 44(8):566-9. PubMed ID: 16194404
[TBL] [Abstract][Full Text] [Related]
35. Mean platelet volume, red cell distribution width, platelet-to-lymphocyte and neutrophil-to-lymphocyte ratios in patients with ankylosing spondylitis and their relationships with high-frequency hearing thresholds.
Bozan N; Alpaycı M; Aslan M; Cankaya H; Kıroglu AF; Turan M; Ayral A; Senkoy E; Ilter S
Eur Arch Otorhinolaryngol; 2016 Nov; 273(11):3663-3672. PubMed ID: 27034281
[TBL] [Abstract][Full Text] [Related]
36. Erythrocyte sedimentation rate, C-reactive protein level, and serum amyloid a protein for patient selection and monitoring of anti-tumor necrosis factor treatment in ankylosing spondylitis.
de Vries MK; van Eijk IC; van der Horst-Bruinsma IE; Peters MJ; Nurmohamed MT; Dijkmans BA; Hazenberg BP; Wolbink GJ
Arthritis Rheum; 2009 Nov; 61(11):1484-90. PubMed ID: 19877087
[TBL] [Abstract][Full Text] [Related]
37. [Clinical observation on total glucosides of paeony combined with sulfasalazine in treatment of ankylosing spondylitis].
Wang SL; Wang JP; Bian H
Zhongguo Zhong Xi Yi Jie He Za Zhi; 2007 Mar; 27(3):217-9. PubMed ID: 17432680
[TBL] [Abstract][Full Text] [Related]
38. Aerobic capacity and its correlates in patients with ankylosing spondylitis.
Hsieh LF; Wei JC; Lee HY; Chuang CC; Jiang JS; Chang KC
Int J Rheum Dis; 2016 May; 19(5):490-9. PubMed ID: 24754841
[TBL] [Abstract][Full Text] [Related]
39. Effects of sulfasalazine combined with moxibustion methods on patients with cold-dampness obstruction type ankylosing spondylitis.
Liao WJ; Song FJ; Liu HF
Pak J Pharm Sci; 2020 May; 33(3(Special)):1367-1371. PubMed ID: 33361024
[TBL] [Abstract][Full Text] [Related]
40. [Clinical study on treatment of patients with ankylosing spondylitis by Panlongqi tablet].
Zhao FT; Zhao H
Zhongguo Zhong Xi Yi Jie He Za Zhi; 2007 Jun; 27(6):540-2. PubMed ID: 17633369
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
